Etexilate Treatment Dabigatran etexilate is a direct thrombin inhibitor that was initially introduced for oral anticoagulation for the prevention or treatment of venous thrombosis. After the recently concluded phase III trial Randomized Evaluation of Long-Term Anticoagulation Therapy, dabigatran has been approved by the US Food and Drug Administration as a potential replacement for warfarin in ...

BACKGROUND AND PURPOSE In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin. However, concerns exist about potential worse outcomes in dabigatran users if bleeding occurs, given the lack of approved reversal agents. Thus, we examined in-hospital mortality in AF patient...

Dabigatran is a direct thrombin inhibitor indicated for thromboembolism prophylaxis in patients with non-valvular atrial fibrillation. The procedure to manage dabigatran-associated haemorrhages is not well formalized. Conventional haemodialysis has been evaluated with good results. Patients with dabigatran-associated bleeding may be unstable and convective techniques like venovenous haemodiafil...

OBJECTIVES To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. DESIGN Quantitative benefit-harm and economic analyses using a discrete event simulation model to extrapolate the findings of the RE-LY (Rando...

BACKGROUND Dabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA). The aim of this study is to assess the cost-effectiveness (CE) of dabigatran for the treatment and secondary prevention in patients with VTE compared to VKAs in the Dutch setting. METHODS Previously publis...

BACKGROUND The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established. METHODS AND RESULTS We formed new-user cohorts of propensity score-matched elderly patients enrolled in Medicare who initiated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and Dec...

Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits. However, questions have been raised constantly regarding the safety of dabigatran etexilate. Case. A 58-year-old Caucasian male with a history of recurrent paroxysmal atrial f...

BACKGROUND cost of anticoagulation with dabigatran is largely based on estimation of complication rates derived from clinical trials. OBJECTIVE to investigate cost of anticoagulation with dabigatran in comparison with warfarin in clinical practice. METHODS a prospective observational study of patients with non-vavular atrial fibrillation (NVAF) referred to anticoagulation clinic. Patients w...

Dabigatran is an oral thrombin inhibitor that is licensed for stroke prevention in atrial fibrillation and for prevention and treatment of venous thromboembolism. Although dabigatran is administered in fixed doses without routine coagulation monitoring, quantification of the plasma levels of dabigatran is useful to detect accumulation in patients with acute kidney injury, for assessment of its ...

OBJECTIVES This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against each other. BACKGROUND Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinical trials of stroke prevention in atrial fibrillation (AF) are now available for the oral direct ...